Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.71 |
| ▸ | MAOA | P21397 | 4/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12804337 | 0.92 | HDAC6 (0.71) | HDAC6HDAC1MAOAMAOBHDAC3 | |
| SCHEMBL12938916 | 0.88 | HDAC6 (0.72) | HDAC6HDAC1MAOAMAOBHDAC3 | |
| SCHEMBL12805099 | 0.86 | HDAC1 (0.67) | HDAC6HDAC1MAOAMAOBTNF | |
| SCHEMBL12938917 | 0.86 | HDAC6 (0.78) | HDAC6HDAC1MAOAMAOBHDAC3 | |
| SCHEMBL17517481 | 0.84 | MAOA (0.79) | HDAC6HDAC1MAOAMAOBHDAC3 | |
| SCHEMBL12938807 | 0.83 | HDAC6 (0.84) | HDAC6HDAC1MAOAMAOBHDAC3 | |
| SCHEMBL1080466 | 0.83 | HDAC6 (1.00) | HDAC6HDAC1MAOAMAOBHDAC3 | |
| SCHEMBL3718005 | 0.83 | MAOA (0.62) | HDAC6HDAC1MAOAMAOBHDAC3 | |
| SCHEMBL12951710 | 0.82 | HDAC6 (0.49) | HDAC6HDAC1MAOAMAOBTNF | |
| SCHEMBL14891246 | 0.82 | ENPP2 (0.77) | HDAC6HDAC1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456757-B1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-2456757-B1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-05-01 | — | — | EP | disclosed |
| US-8748451-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748451-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130281484-A1 | HDAC Inhibitors and Therapeutic Methods of Using Same | UNIV ILLINOIS (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281484-A1 | HDAC Inhibitors and Therapeutic Methods of Using Same | UNIV ILLINOIS (US) | 2013-10-24 | — | — | US | disclosed |
| US-8431538-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431538-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | KOZIKOWSKI ALAN (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | KOZIKOWSKI ALAN (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2456757-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Board of Trustees of the University of Illinois (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011011186-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | HDAC1, HDAC9, HDAC5 | HDAC6 7/4885HDAC1 1/4885MAOA 672/4885 |
| US-20130281484-A1 | HDAC Inhibitors and Therapeutic Methods of Using Same | HDAC1, HDAC9, HDAC5 | HDAC6 7/4885HDAC1 1/4885MAOA 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.